Alzheimer’s disease in the real world: Where evidence matters most
Alzheimer’s disease burden and the current therapy pipeline Alzheimer’s disease remains the leading...
A recent CNBC article used HealthVerity real-world data (RWD) to highlight a shortage of estrogen patches that is visible in RWD as demand for menopause support skyrockets. Menopause affects millions of women, yet it has long remained one of the...
Alzheimer’s disease burden and the current therapy pipeline Alzheimer’s disease remains the leading...
Identifying the gaps in today’s real-world data The 2025 IMPACCT Real-World Evidence Summit brought...
When two federal agencies, the National Center for Science and Engineering Statistics (NCSES) and...
October is Breast Cancer Awareness Month. While pink ribbons and fundraising campaigns help bring...
AI changed how we discover medicines. What's next? In just a few years, artificial intelligence...
In a recent webinar, the HealthVerity team including Alexa Woodward, Ph.D., Director of Strategic...
When we introduced HealthVerity eXOs, an agentic AI platform powered by Medeloop, in our recent...
The evolution of heart failure treatment and research Heart failure remains one of the most...
The rise of GLP-1 therapies and the evolution of obesity treatment Over 40% of adults in the U.S....
Recently, HealthVerity COO and co-founder Andrew Goldberg spoke at a timely webinar: Back to...
On July 1, 2026, the Centers for Medicare and Medicaid Services (CMS) launched the Medicare Bridge demonstration, extending GLP-1 access to certain Medicare beneficiaries.